SP Group (SPG) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
19 Dec, 2025Deal rationale and strategic fit
Acquisition of Idé-Pro provides advanced prototyping, large-part injection moulding, die-casting, and digital platform capabilities, expanding technological offerings and supporting a One-Stop Shop strategy.
Strengthens position as a leading plastics company in Northern Europe, supporting growth ambitions toward 2030 and expanding presence in India for growth in Asia.
Idé-Pro's strong sales team, customer proximity in Europe, and digital platform enable fast delivery and efficient production.
Enhances ability to deliver across the value chain, from R&D to serial production, especially for defence, healthcare, cleantech, and foodtech sectors.
In-house tool production and a platform in India enhance flexibility, competitiveness, and service to local customers.
Financial terms and conditions
Transaction based on an enterprise value of DKK 700 million, fully paid in cash and debt financed, with a locked-box date of June 30, 2025; signing and closing occurred simultaneously.
Equity value on a debt-free basis is DKK 671.8 million after working capital adjustments.
Idé-Pro reported EBITDA of DKK 92 million for the year ended June 30, 2025.
Acquisition cost is higher than previous deals due to Idé-Pro's size and strategic value.
Transaction costs will impact current year and 2025 results, but no change to previously announced expectations.
Synergies and expected cost savings
Annual synergies of DKK 20–25 million expected within two years, mainly from in-house tool production and cross-selling.
Revenue increase of DKK 450–500 million and EBITDA impact of DKK 105–120 million projected for 2026, including synergies.
Increased efficiency and earnings anticipated from expanded in-house toolmaking capacity.
Cost savings anticipated by moving tool production in-house, reducing reliance on external suppliers.
Latest events from SP Group
- Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 202426 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025 - Revenue down 3.3% in 9M 2025, but guidance and growth outlook remain stable.SPG
Q3 202520 Nov 2025 - H1 2025 saw revenue and earnings decline, but margin guidance and growth projects remain on track.SPG
Q2 202520 Aug 2025 - Strong own-brand and healthcare sales drove double-digit profit and margin growth in 2024.SPG
Q3 202413 Jun 2025 - Record Q1 growth and margin expansion, with 2025 outlook unchanged.SPG
Q1 20256 Jun 2025